These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6937954)

  • 41. Evaluation of the E-test for susceptibility testing of the Bacteroides fragilis group. Danish study group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1994 Jun; 102(6):446-50. PubMed ID: 8068304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experimental and clinical study of the biliary excretion of cefamandole (author's transl)].
    Brogard JM; Pinget M; Arnaud JP; Dorner M; Adloff M; Lavillaureix J
    Pathol Biol (Paris); 1981 Jan; 29(1):25-30. PubMed ID: 7010273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefamandole--effectiveness against anaerobes: supplementary remarks.
    Levine LR
    Scand J Infect Dis Suppl; 1980; suppl 25():94-5. PubMed ID: 7010543
    [No Abstract]   [Full Text] [Related]  

  • 44. Synergistic action of erythromycin and cefamandole against Bacteroides fragilis subsp. fragilis.
    Griffith RS; Brier GL; Wolny JD
    Antimicrob Agents Chemother; 1977 May; 11(5):813-6. PubMed ID: 879736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of ceftizoxime and comparative compounds against Bacteroides fragilis in a mouse model of anaerobic infection.
    Grappel SF; Phillips L; Actor P
    J Antibiot (Tokyo); 1984 Apr; 37(4):384-8. PubMed ID: 6327593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic.
    Darland G; Birnbaum J
    Antimicrob Agents Chemother; 1977 Apr; 11(4):725-34. PubMed ID: 856025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inactivation of cephalosporins by Bacteroides.
    Tally FP; O'Keefe JP; Sullivan NM; Gorbach SL
    Antimicrob Agents Chemother; 1979 Nov; 16(5):565-71. PubMed ID: 525995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-vitro sensitivity tests and in-vivo efficacy of cephalosporins against Bacteroides fragilis.
    Brook I
    J Antimicrob Chemother; 1990 Jul; 26(1):158-61. PubMed ID: 2211440
    [No Abstract]   [Full Text] [Related]  

  • 49. Influence of R-plasmid mediated beta-lactamase production on the therapeutic efficacy of cefoxitin and cefamandole in experimental chemotherapy.
    Marre R; Schulz E; Freiesleben H
    J Antimicrob Chemother; 1980 Sep; 6(5):633-8. PubMed ID: 6997259
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pharmacokinetics of cefamandole in rabbits].
    Klimova VS; Bobrov VI; Nazarova OI; Skala LZ; Iakovlev VP
    Antibiotiki; 1982 Dec; 27(12):34-8. PubMed ID: 7165292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefamandole, cefuroxime and cefoxitin.
    Drug Ther Bull; 1979 Apr; 17(9):35-6. PubMed ID: 446269
    [No Abstract]   [Full Text] [Related]  

  • 52. Cefamandole treatment of pulmonary infection caused by gram-negative rods.
    Mandell GL
    Scand J Infect Dis Suppl; 1980; suppl 25():107-11. PubMed ID: 7010535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A standardised and reproducible model of intraabdominal infection and abscess formation in rats.
    Bosscha K; Nieuwenhuijs VB; Gooszen AW; van Duijvenbode-Beumer H; Visser MR; Verweij WR; Akkermans LM
    Eur J Surg; 2000 Dec; 166(12):963-7. PubMed ID: 11152259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and experimental evaluation of cefoxitin therapy.
    Webb D; Thadepalli H; Bach V; Roy I
    Chemotherapy; 1979; 25(4):233-42. PubMed ID: 378578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Migration of rat peritoneal cells after intra-abdominal infection with Bacteroides fragilis and Escherichia coli.
    Verweij WR; Namavar F; Schouten WF; de Graaff J; MacLaren DM
    J Gen Microbiol; 1993 Aug; 139(8):1739-44. PubMed ID: 8409916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
    Joiner K; Lowe B; Dzink J; Bartlett JG
    J Infect Dis; 1982 Apr; 145(4):561-8. PubMed ID: 7069236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activities of cefoxitin in vitro and in vivo: a study in patients with biliary tract infection undergoing percutaneous transhepatic biliary drainage.
    Masuda G; Tabata I; Isawa T; Yamazaki E; Mizuoka K
    Methods Find Exp Clin Pharmacol; 1986 Jun; 8(6):367-72. PubMed ID: 3526054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins.
    Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T
    Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibiotic prophylaxis in vascular surgery: pharmacokinetic study of four commonly used cephalosporins.
    Fradet G; Brister S; Richards GK; Prentis J; Brown RA; Chiu RC; Mulder DS
    J Vasc Surg; 1986 Mar; 3(3):535-9. PubMed ID: 3512862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia.
    Wallace RJ; Niefield SL; Waters S; Waters B; Awe RJ; Wiss K; Martin RR; Greenberg SB
    Antimicrob Agents Chemother; 1982 Feb; 21(2):231-5. PubMed ID: 7041813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.